The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment | Zendy

Henry Rodriguez | Zendy; Jean C. Zenklusen | Zendy; Louis M. Staudt | Zendy; James H. Doroshow | Zendy; Douglas R. Lowy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment

Author(s) -

Henry Rodriguez,

Jean C. Zenklusen,

Louis M. Staudt,

James H. Doroshow,

Douglas R. Lowy

Publication year - 2021

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2021.02.055

Subject(s) - proteogenomics , precision oncology , biology , precision medicine , cancer , cancer treatment , clinical trial , clinical oncology , medical physics , oncology , computational biology , medicine , bioinformatics , genome , genomics , genetics , gene

When it comes to precision oncology, proteogenomics may provide better prospects to the clinical characterization of tumors, help make a more accurate diagnosis of cancer, and improve treatment for patients with cancer. This perspective describes the significant contributions of The Cancer Genome Atlas and the Clinical Proteomic Tumor Analysis Consortium to precision oncology and makes the case that proteogenomics needs to be fully integrated into clinical trials and patient care in order for precision oncology to deliver the right cancer treatment to the right patient at the right dose and at the right time.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research